Caspase 10 levels are increased following DNA damage in a p53-dependent manner

Cancer Biology and Therapy

Volumn 2, Issue 6, 2003, Pages 707-712

  Rikhof, Bart ^a   Corn, Paul G ^a   El Deiry, Wafik S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Caspase 10; DNA damage; p53

Indexed keywords

CASP10 PROTEIN, HUMAN; CASPASE; CASPASE 10; ETOPOSIDE; MESSENGER RNA; NUCLEIC ACID SYNTHESIS INHIBITOR; PROTEIN P53;

ADENOVIRUS; ARTICLE; BIOSYNTHESIS; COLON TUMOR; COMPARATIVE STUDY; DNA DAMAGE; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LUNG TUMOR; METABOLISM; OSTEOSARCOMA; OVARY TUMOR; PATHOLOGY; PROMOTER REGION; SERODIAGNOSIS; TUMOR CELL LINE; UPREGULATION; WESTERN BLOTTING;

ADENOVIRIDAE; BLOTTING, WESTERN; CASPASE 10; CASPASES; CELL LINE, TUMOR; COLONIC NEOPLASMS; DNA DAMAGE; ETOPOSIDE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; NUCLEIC ACID SYNTHESIS INHIBITORS; OSTEOSARCOMA; OVARIAN NEOPLASMS; PRECIPITIN TESTS; PROMOTER REGIONS (GENETICS); RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 4444344019     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.2.6.626     Document Type: Article

References (49)

1. Sharpless NE, DePinho RA. p53: Good cop/bad cop. Cell 2002; 110:9-12. (Pubitemid 34874601)
2. Hahn WC, Weinberg RA. Modelling the molecular circuitry of cancer. Nat Rev Cancer 2002; 2:331-41.
3. Vousden KH. Activation of the p53 tumor suppressor protein. Biochim Biophys Acta 2002; 1602:47-59. (Pubitemid 34311899)
4. Vousden KH, Lu X. Live or let die: The cell's response to p53. Nat Rev Cancer 2002; 2:594-604. (Pubitemid 37328926)
5. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992; 70:523-6.
6. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253:49-53. (Pubitemid 21917115)
7. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998; 282:1497-501. (Pubitemid 28538613)
8. Waldman T, Kinzler KW, Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 1995; 55:5187-90.
9. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407:770-6.
10. Wu GS, Burns TF, McDonald 3rd ER, Jiang W, Meng R, Krantz ID, et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 1997; 17:141-3.
11. Sax JK, Fei P, Murphy ME, Bernhard E, Korsmeyer SJ, El-Deiry WS. BID regulation by p53 contributes to chemosensitivity. Nat Cell Biol 2002; 4:842-9. (Pubitemid 35331358)
12. MacLachlan TK, and El-Deiry WS. Apoptotic threshold is lowered by p53 transactivation of caspase-6. Proc Natl Acad Sci USA 2002; 99:9492-7. (Pubitemid 34764641)
13. Ryan KM, Phillips AC, Vousden KH. Regulation and function of the p53 tumor suppressor protein. Curr Opin Cell Biol 2001; 13:332-337. (Pubitemid 32429498)
14. Vousden KH p53: Death star. Cell 2000; 103:691-4.
15. Nicholson DW. Caspase structure, proteolytic substrates, and function during apoptotic cell death. Cell Death Differ 1999; 6:1028-1042.
16. Nunez G, Benedict MA, Hu Y, Inohara N. Caspases: The proteases of the apoptotic pathway. Oncogene 1998; 17:3237-45.
17. Xiao C, Yang BF, Asadi N, Beguinot F, Hao C. Tumor necrosis factor-related apoptosis-inducing ligand-induced death-inducing signaling complex and its modulation by c-FLIP and PED/PEA-15 in glioma cells. J Biol Chem 2002; 277:25020-5. (Pubitemid 34951805)
18. Kischkel FC, Lawrence DA, Tinel A, LeBlanc H, Virmani A, Schow P, et al. Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J Biol Chem 2001; 276:46639-46.
19. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002; 2:420-30. (Pubitemid 37328939)
20. Muzio M, Stockwell BR, Stennicke HR, Salvesen GS, Dixit VM. An induced proximity model for caspase-8 activation. J Biol Chem 1998; 273:2926-30. (Pubitemid 28133943)
21. Wang J, Chun HJ, Wong W, Spencer DM, Lenardo MJ. Caspase-10 is an initiator caspase in death receptor signaling. Proc Natl Acad Sci USA 2001;98:13884-8. (Pubitemid 33115993)
22. Hsu H, Huang J, Shu HB, Baichwal V, Goeddel DV. TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity 1996; 4:387-96. (Pubitemid 26174054)
23. Kelliher MA, Grimm S, Ishida Y, Kuo F, Stanger BZ, Leder P. The death domain kinase RIP mediates the TNF-induced NF-kappaB signal. Immunity 1998; 8:297-303. (Pubitemid 28188890)
24. Wu GS, EI-Deiry WS. Apoptotic death of tumor cells correlates with chemosensitivity, independent of p53 or bcl-2. Clin Cancer Res 1996; 2:623-33. (Pubitemid 26135334)
25. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75:817-25.
26. Takimoto R, MacLachlan TK, Dicker DT, Niitsu Y, Mori T, el-Deiry WS. BRCA1 transcriptionally regulates damaged DNA binding protein (DDB2) in the DNA repair response following UV-irradiation. Cancer Biol Ther 2002; 1:177-86.
27. el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. Definition of a consensus binding site for p53. Nat Genet 1992; 1:45-9.
28. Gupta S, Radha V, Furukawa Y, Swarup G. Direct transcriptional activation of human caspase- 1 by tumor suppressor p53. J Biol Chem 2001; 276:10585-8. (Pubitemid 38089225)
29. Zheng TS, Hunot S, Kuida K, Flavell RA. Caspase knockouts: Matters of life and death. Cell Death Differ 1999; 6:1043-53.
30. Thornberry NA ,Lazebnik Y. Caspases: Enemies within. Science 1998; 281:1312-6.
31. Munsch D, Watanabe-Fukunaga R, Bourdon JC, Nagata S, May E, Yonish-Rouach E, Reisdorf P. Human and mouse Fas (APO-1/CD95) death receptor genes each contain a p53-responsive element that is activated by p53 mutants unable to induce apoptosis. J Biol Chem 2000; 275:3867-72. (Pubitemid 30094610)
32. Muller M, Strand S, Hug H, Heinemann EM, Walczak H, Hofmann WJ, et al. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest 1997; 99:403-13. (Pubitemid 27414797)
33. Ruiz-Ruiz C, Robledo G, Cano E, Redondo JM, Lopez-Rivas A. Characterization of p53-mediated up-regulation of CD95 gene expression upon genotoxic treatment in human breast tumor cells. J Biol Chem 2003; 278:31667-75. (Pubitemid 37048345)
34. Friesen C, Herr I, Krammer PH, Debatin KM. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 1996; 2:574-7. (Pubitemid 26150685)
35. Friesen C, Fulda S, Debatin KM. Induction of CD95 ligand and apoptosis by doxorubicin is modulated by the redox state in chemosensitive- and drug-resistant tumor cells. Cell Death Differ 1999; 6:471-80. (Pubitemid 29245961)
36. Fulda S, Sieverts H, Friesen C, Herr I, Debatin KM. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res 1997; 57:3823-9. (Pubitemid 27381230)
37. Engels IH, Stepczynska A, Stroh C, Lauber K, Berg C, Schwenzer R, et al. Caspase-8/FLICE functions as an executioner caspase in anticancer drug-induced apoptosis. Oncogene 2000; 19:4563-73.
38. Wesselborg S, Engels IH, Rossmann E, Los M, Schulze-Osthoff K. Anticancer drugs induce caspase-8/FLICE activation and apoptosis in the absence of CD95 receptor/ligand interaction. Blood 1999; 93:3053-63. (Pubitemid 29200798)
39. Micheau O, Solary E, Hammann A, Martin F, Dimanche-Boitrel MT. Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity. J Natl Cancer Inst 1997; 89:783-9. (Pubitemid 27242279)
40. Friesen C, Fulda S, Debatin KM. Cytotoxic drugs and the CD95 pathway. Leukemia 1999; 13:1854-8.
41. Wu XX, Kakehi Y, Mizutani Y, Kamoto T, Kinoshita H, Isogawa Y, et al. Doxorubicin enhances TRAIL-induced apoptosis in prostate cancer. Int J Oncol 2002; 20:949-54.
42. Lacour S, Hammann A, Wotawa A, Corcos L, Solary E, Dimanche-Boitrel MT Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. Cancer Res 2001; 61:1645-51. (Pubitemid 34292600)
43. Bonavida B, Tsuchitani T, Zighelboim J, Berek JS. Synergy is documented in vitro with low-dose recombinant tumor necrosis factor, cisplatin, and doxorubicin in ovarian cancer cells. Gynecol Oncol 1990; 38:333-9. (Pubitemid 20362551)
44. Fernandes-Alnemri T, Armstrong RC, Krebs J, Srinivasula SM, Wang L, Bullrich F, et al. In vitro activation of CPP32 and Mch3 by Mch4, a novel human apoptotic cysteine protease containing two FADD-like domains. Proc Natl Acad Sci USA 1996; 93:7464-9.
45. Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA, et al. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 2000; 6:529-35. (Pubitemid 30305902)
46. Harada K, Toyooka S, Shivapurkar N, Maitra A, Reddy JL, Matta H, et al. Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines. Cancer Res 2002; 62:5897-901. (Pubitemid 35204751)
47. Park WS, Lee JH, Shin MS, Park JY, Kim HS, Kim YS, et al. Inactivating mutations of the caspase-10 gene in gastric cancer. Oncogene 2002; 21:2919-25.
48. Shin MS, Kim HS, Kang CS, Park WS, Kim SY, Lee SN, et al. Inactivating mutations of CASP10 gene in nonHodgkin lymphomas. Blood 2002; 99:4094-9. (Pubitemid 35332052)
49. Yasumoto J, Imai Y, Takahashi A, Ohnishi K, Yuki K, Kirita T, et al. Analysis of apoptosis-related gene expression after X-ray irradiation in human tongue squamous cell carcinoma cells harboring wild-type or mutated p53 gene. J Radiat Res (Tokyo) 2003; 44:41-5. (Pubitemid 38738754)